---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-189569"
form_type: "8-K"
ticker: "VCNX"
cik: "0001205922"
company_name: "VACCINEX, INC."
filed_at: "2024-07-31T23:59:59+00:00"
generated_at: "2026-05-31T14:16:49.003189+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Vaccinex reports positive SIGNAL-AD Phase 1b/2 data for pepinemab in Alzheimer's

## Summary
- Primary safety endpoint met: pepinemab well-tolerated; no serious treatment-related adverse events.
- Secondary endpoint: statistically significant increase in FDG-PET signal in medial temporal cortex (p=0.0297) in MCI patients over 12 months.
- Results echo prior Phase 2 Huntington's data, suggesting similar mechanism targeting astrocyte activation.
- Company actively pursuing a pharmaceutical partner for late-stage development in Alzheimer's disease.
- Pepinemab has been well-tolerated in over 600 patients across AD, HD, and MS trials.

## SEC filing metadata
- accession: 0001193125-24-189569
- form_type: 8-K
- ticker: VCNX
- cik: 0001205922
- company_name: VACCINEX, INC.
- filed_at: 2024-07-31T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1205922/000119312524189569/0001193125-24-189569-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1205922/000119312524189569/d858316d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-189569
- JSON: https://secwatch.observer/filing/0001193125-24-189569.json
- Plain text: https://secwatch.observer/filing/0001193125-24-189569.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.